Health Catalyst Statistics
Total Valuation
HCAT has a market cap or net worth of $428.59 million. The enterprise value is $349.68 million.
| Market Cap | 428.59M |
| Enterprise Value | 349.68M |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, after market close.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
HCAT has 59.03 million shares outstanding. The number of shares has increased by 5.60% in one year.
| Shares Outstanding | 59.03M |
| Shares Change (YoY) | +5.60% |
| Shares Change (QoQ) | +1.92% |
| Owned by Insiders (%) | 2.97% |
| Owned by Institutions (%) | 88.98% |
| Float | 57.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 17.90 |
| PS Ratio | 1.44 |
| Forward PS | 1.33 |
| PB Ratio | 1.20 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.31, with a Debt / Equity ratio of 0.70.
| Current Ratio | 4.31 |
| Quick Ratio | 4.14 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 15.38 |
Financial Efficiency
Return on equity (ROE) is -28.20% and return on invested capital (ROIC) is -18.94%.
| Return on Equity (ROE) | -28.20% |
| Return on Assets (ROA) | -14.90% |
| Return on Capital (ROIC) | -18.94% |
| Revenue Per Employee | $228,302 |
| Profits Per Employee | -$81,188 |
| Employee Count | 1,300 |
| Asset Turnover | 0.42 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, HCAT has paid $400,000 in taxes.
| Income Tax | 400,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.06% in the last 52 weeks. The beta is 1.32, so HCAT's price volatility has been higher than the market average.
| Beta (5Y) | 1.32 |
| 52-Week Price Change | -43.06% |
| 50-Day Moving Average | 6.53 |
| 200-Day Moving Average | 7.78 |
| Relative Strength Index (RSI) | 63.35 |
| Average Volume (20 Days) | 572,958 |
Short Selling Information
The latest short interest is 2.07 million, so 3.50% of the outstanding shares have been sold short.
| Short Interest | 2.07M |
| Short Previous Month | 1.89M |
| Short % of Shares Out | 3.50% |
| Short % of Float | 3.60% |
| Short Ratio (days to cover) | 3.89 |
Income Statement
In the last 12 months, HCAT had revenue of $296.79 million and -$105.54 million in losses. Loss per share was -$1.84.
| Revenue | 296.79M |
| Gross Profit | 132.48M |
| Operating Income | -114.80M |
| Pretax Income | -105.14M |
| Net Income | -105.54M |
| EBITDA | -67.70M |
| EBIT | -112.46M |
| Loss Per Share | -$1.84 |
Balance Sheet
The company has $327.79 million in cash and $248.87 million in debt, giving a net cash position of $78.91 million or $1.34 per share.
| Cash & Cash Equivalents | 327.79M |
| Total Debt | 248.87M |
| Net Cash | 78.91M |
| Net Cash Per Share | $1.34 |
| Equity (Book Value) | 357.21M |
| Book Value Per Share | 6.05 |
| Working Capital | 304.93M |
Cash Flow
In the last 12 months, operating cash flow was -$17.23 million and capital expenditures -$12.61 million, giving a free cash flow of -$29.85 million.
| Operating Cash Flow | -17.23M |
| Capital Expenditures | -12.61M |
| Free Cash Flow | -29.85M |
| FCF Per Share | -$0.51 |
Margins
Gross margin is 44.64%, with operating and profit margins of -38.68% and -35.56%.
| Gross Margin | 44.64% |
| Operating Margin | -38.68% |
| Pretax Margin | -35.43% |
| Profit Margin | -35.56% |
| EBITDA Margin | -22.81% |
| EBIT Margin | -37.89% |
| FCF Margin | -10.06% |
Dividends & Yields
HCAT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.60% |
| Shareholder Yield | -5.60% |
| Earnings Yield | -24.63% |
| FCF Yield | -6.96% |
Analyst Forecast
The average price target for HCAT is $12.30, which is 69.42% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.30 |
| Price Target Difference | 69.42% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
HCAT has an Altman Z-Score of -1.11 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.11 |
| Piotroski F-Score | 3 |